U.S. markets closed

Dr. Reddy's Laboratories Limited (RDY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
64.33-1.20 (-1.83%)
At close: 4:00PM EST

64.33 0.00 (0.00%)
After hours: 4:15PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Previous Close65.53
Bid60.00 x 800
Ask64.77 x 1400
Day's Range63.89 - 64.59
52 Week Range33.33 - 73.50
Avg. Volume189,066
Market Cap10.797B
Beta (5Y Monthly)-0.01
PE Ratio (TTM)45.82
Earnings DateN/A
Forward Dividend & Yield0.33 (0.51%)
Ex-Dividend DateJul 10, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-10% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase

    Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase

    Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.

  • Reuters

    India trials for Russia's 'Sputnik-V' vaccine could start in next few weeks - exec

    Dr Reddy's Laboratories Ltd could begin late-stage Indian clinical trials of Russia's potential coronavirus vaccine in the next few weeks, an executive at the Indian drugmaker said on Tuesday. Indian trials of the Sputnik-V vaccine candidate, being developed by Russia's sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country, Deepak Sapra, CEO for API and pharmaceutical services at Dr. Reddy's, told Reuters. "We want to get to the first step - which is the commencement of the clinical trials by getting the necessary approvals from the Indian regulators - within the next few weeks," Sapra said.

  • Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
    Motley Fool

    Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

    Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.